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Sedation in the context of terminal care has been a hotly
debated topic for many years.1-4 In 1990 a report was published
claiming that 52% of moribund patients required sleep-
inducing sedation to control physical suffering.5 This
stimulated a lot of discussion in palliative care circles, with
many physicians being surprised at the apparent high
percentage of patients needing sedation. Subsequent studies
carried out in various centres throughout the world showed
that the prevalence of sedation varied a great deal (1 - 72%).1 It
has been suggested that this wide variation can be attributed to
differences in the terminology used, differences in the
application of modern palliative care in different parts of the
world and possibly varying standards and criteria for the use
of sedation.1,6-8 Adding to the concern has been the accusation
that in reality sedation of dying patients is the equivalent of
‘slow euthanasia’.2 There is therefore a need to clarify and
carefully define the terms used with regard to sedation of
dying patients, and to develop guidelines that are
internationally recognised and accepted by both health
professionals and the public.
Objectives
The aim of the study was to document the use of sedation for
refractory symptoms in patients admitted to an independent
palliative care unit.
Method
A prospective descriptive study was carried out of all patients
admitted to Sungardens Hospice, Pretoria, between January
and June 2002, whose symptoms were unresponsive to
standard palliative care measures and who required sedation to
relieve their distress.
Setting
Sungardens Hospice originated in 1987 as  a nurse-led
domiciliary service providing care for dying patients in the
445
Use of sedation to relieve refractory symptoms in dying
patients
David Cameron, Douglas Bridge, Julia Blitz-Lindeque
Objectives. To document the use of sedation for refractory
symptoms in patients admitted to an independent palliative
care unit.
Method. A prospective descriptive study.
Setting. The 7-bed inpatient unit at Sungardens Hospice,
Pretoria.
Subjects. Patients who required sedation for refractory
symptoms in addition to normal palliative care treatment
between January and June 2002.
Findings. Twenty of 100 consecutive patients admitted
required sedation. All had advanced cancer. Their mean age
was 68 years. Thirty-six per cent were men and 64% women.
Indications. Agitated delirium was the most common reason
(45%) for using sedation, followed by intractable vomiting
due to inoperable malignant intestinal obstruction in 25% of
patients. Three patients with persistent convulsions or
myoclonic jerking and 2 patients with severe refractory
dyspnoea required some sedation. Intractable pain was the
main reason for sedation in only 1 patient.
Survival. Mean survival following the start of sedation was 92
hours/3.8 days (range 6 - 369 hours/0.25 - 19.4 days). The
combined mean survival recorded in 9 other studies was 57
hours/2.4 days (range 36 - 93.6 hours/1.5 - 3.9 days).
Medication. The main drugs used for sedation were
midazolam and haloperidol.  The mean dosage for
midazolam was 18.5 mg/24 hours (range 7.5 - 40 mg) and for
haloperidol 8 mg/24 hours (range 5 - 10 mg).
For pain relief the mean daily dose of parenteral morphine
was 76 mg (range 15 - 260 mg).
Conclusion. Use of sedation for the relief of refractory
symptoms at Sungardens Hospice is in line with several
studies reported in the international literature.
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greater Pretoria area (population 1.48 million, 1996 census). It
was based on the principles of the modern hospice movement
developed in England during the 1960s under Dr Cicely
Saunders at St Christopher’s Hospice, London.
Sungardens Hospice gradually expanded and in 1990 a 7-
bed inpatient unit (IPU) was opened to provide short-stay care
for a wide range of terminal patients. In addition to terminal
care, patients are also admitted for symptom control and
occasionally to give the patient’s family a period of respite.
Three part-time doctors provide the medical care in the IPU.
Since 1998 an average of 218 patients have been admitted to
the IPU each year. The majority (76%) of these patients have
advanced cancer. Over the last few years the number of AIDS
patients has increased steadily. By 2002, patients suffering from
AIDS made up 12% of admissions and 33% of the patients in
domiciliary care. The average length of stay in the IPU is 15
days and the Unit has a bed occupancy rate of 82%. One-third
of the patients admitted are discharged to domiciliary care
once their symptoms have been controlled.
Patient selection
All patients who received sedating drugs (apart from sleeping
tablets) were included in the study. This selection can be
criticised for being too broad.6 However, as the difference
between sedation for mild anxiety or mild confusion and
sedation for refractory symptoms is sometimes not clear-cut in
dying patients, it was felt that the inclusion of all patients
would minimise selection bias and underreporting.
The study began on 1 January 2002 and was completed on 
15 June after 100 consecutive patients had been admitted. No




Twenty patients required sedation. All had advanced cancer.
Their mean age was 68 years (range 49 - 88 years). The mean
age of the whole group was 62.2 years (range 21 - 93 years).
The slight difference was due to the younger ages (mean 32.2
years) of the 16 patients admitted with AIDS, none of whom
required sedation. The gender ratio was 36% men and 64%
women. This is very similar to the gender ratio (34:66) of the
entire group of patients admitted during this period.
Reason for sedation
The main refractory symptoms requiring sedation were
delirium (45%), nausea and vomiting (25%), convulsions (15%),
dyspnoea (10%) and pain (5%) (Table I).
All patients had signs of very advanced cancer and had been
referred for palliative care. Malignant intestinal obstruction
was present in 5 patients, 2 others had extensive bone
metastases, 1 patient had severe jaundice, 1 had brain
metastases, 2 patients had gastro-intestinal tract (GIT) bleeding
and 1 had myoclonic jerking due to opioid-induced
neurotoxicity.
Sedation — response and outcome
It took an average of 19 hours (range 1 - 96 hours, median 11.5
hours) for the sedation to be fully effective. Patients survived
an average of 92 hours/3.8 days (range 6 - 369 hours/0.25 -
19.4 days) after sedation was started.
Medication used
Morphine sulphate and transdermal fentanyl were the only
opioids used. For ease of comparison, the fentanyl dose was
converted to its parenteral morphine equivalent (PME)
according to the manufacturer’s recommendation. The mean
dosage of morphine used was 76.5 mg/24 hours (range 15 - 260
mg/24 h) (Table II).
For sedation, midazolam and haloperidol were the main
drugs used. In all but 1 case these drugs were given by the
subcutaneous (SC) route using a syringe driver. One patient
was given midazolam intravenously because of sudden severe
dyspnoea that was refractory to all other measures. In the 12
cases where midazolam was used, the mean dosage was 18.5
mg/24 hours (range 7.5 - 40 mg/24 h). Haloperidol was used
in 13 cases, with a mean dosage of 8 mg/24 hours (range 5 - 10
mg/24 h).
Hydration
Four patients were receiving intravenous (IV) or SC fluids at
the time sedation was started. These fluids were not
discontinued. Four patients were able to continue some oral
fluids, while the remainder received routine mouth care and
had water sprayed frequently into their mouths. During this
project, parenteral fluids were not commenced after sedation
had begun. The possible use of IV or SC fluids was, however,
discussed with all patients and their families before sedation.
Their wishes were the main determining factor in deciding
what should be done about maintaining hydration artificially.
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Table I. Refractory symptoms requiring the use of sedation in 20
patients admitted to Sungardens Hospice between January and
June 2002
Refractory symptoms Numbers %
Agitated delirium 9 45
Intractable vomiting 5 25
Convulsions/myoclonic jerking 3 15




All patients and/or their families were fully informed and
consented to the use of sedation. In the case of the delirious
patients, the closest family member gave consent on their
behalf.
Ethical approval
Approval to conduct this research project was obtained from
the ethics committees of Sungardens Hospice and the
University of Cape Town.
Discussion
Terminology
Mild sedation, especially with benzodiazepines, is commonly
used in palliative care to relieve insomnia and mild anxiety
unresponsive to non-drug measures. Patients with severe
symptoms such as agitated delirium, dyspnoea, intractable
vomiting, convulsions and severe pain may require large doses
of a variety of drugs, including anti-emetics, opioids,
neuroleptics, anticonvulsants and even anaesthetic agents such
as ketamine, all of which may cause some degree of sedation as
a side-effect.9-11
Deep sedation, enough to induce complete loss of
consciousness, is occasionally needed in extreme situations in
dying cancer patients when massive haemorrhage, massive
pulmonary embolism or complete airway obstruction occurs.11-14
Only 1 patient included in this study required IV
midazolam for sudden severe dyspnoea. Before this he had
been extremely ill with advanced carcinoma of the pancreas
complicated by partial intestinal obstruction, severe jaundice
and a left-sided pleural effusion. He began vomiting, then
developed severe dyspnoea and coughed up frothy pink
sputum. He may have aspirated or developed acute pulmonary
oedema. He did not respond to oxygen, IV furosemide or IV
fentanyl, so midazolam was given very slowly intravenously. A
total dose of 7.5 mg was eventually given before his distress
subsided. The patient died 10 minutes later. This dose is higher
than the usual loading dose of 0.5 - 1.5 mg recommended in
normal circumstances.9 However, in such an emergency in a
dying patient, an anaesthetising dose of a rapidly acting
sedative, such as midazolam, is recommended.10
Terminal restlessness has many different causes.7,11 Drug
toxicity, hypercalcaemia, urine retention and faecal impaction
can be corrected relatively easily; however, in many patients
terminal restlessness is multifactorial and irreversible. In such
situations, sedation is an effective option.
Many doctors and nurses have reservations about the use of
deep sedation in dying patients. Is sedation being used because
of lack of skill in controlling terminal symptoms by non-
sedating means? Is such sedation merely euthanasia in
disguise?14,15 Is ‘terminal sedation’ a self-fulfilling prophecy,
especially if the normal means of sustaining life such as food
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Table II. Dosages of morphine, midazolam and haloperidol used at Sungardens Hospice compared with dosages used in four
other studies 
Parenteral morphine equivalent (mg/24 h) Midazolam (mg/24 h) Haloperidol (mg/24 h)
Sungardens Mean: 76.5 Mean: 18.5 Mean: 8
Range: 15 - 260 Range: 7.5 - 40 Range: 5 - 10
Number: 20 (100%) Number: 12 (60%) Number: 13 (65%)
Turner et al.31* Mean: 66.5 Mean: not stated
Range: 0 - 360 Range: 2.5 - 47
Number: 43 (86%) Number: not stated
Thorns and Sykes 32* Mean: 55.5
Range: not stated
Number: 212 (89%)
Morita et al.33* Mean: 272/48 hrs Mean: 26 Mean: 5
(OME)† Range: 0.5 - 100 Range: 0.75 - 25
= 68/24 h (PME) Number: 48 (23%) Number: 89 (43%)




Range: 5 - 180
Number: 69 (71%)
*The studies by Turner et al.,31 Thorns and Sykes,32 and Morita et al.33 involved all consecutive admissions, not just those requiring sedation.
†Conversion ratio of 2:1 can be used from oral morphine equivalent (OME) to parenteral morphine equivalent (PME). Consensus statement of the European  Association for Palliative
Care.34 
‡Combined results of a multicentre study.
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and water have been withdrawn at the same time that sedation
has been introduced?
Concern about these issues has prompted some to propose
new terms to replace terminal sedation. After conducting a
survey of 61 international experts in 1998, Chater et al.16
proposed that the phrase ‘sedation for intractable distress in
the dying’ be used in place of terminal sedation. However, this
is a rather cumbersome term.
Morita et al.17 have suggested that the term ‘palliative
sedation therapy’ be used. They define this as ‘the use of
sedative medications to relieve untraceable and refractory
distress by reduction in patient consciousness’. The term
‘palliative sedation’ removes the stigma associated with
terminal sedation and places the emphasis on the purpose of
the sedation rather than on the outcome. It sets out clearly the
aim, the means and the extent of the sedation.
However, if sedation is seen as the desired outcome, it may
discourage regular review and a continued search for non-
sedating alternatives. Regular review is a hallmark of good
care and should continue even when sedation is used. The
amount of sedation can sometimes be reduced after the distress
has been relieved for a short while.18-20 In other cases the
sedation needs to be continued until the patient dies.
Sedation and life expectancy
It is interesting to note that sedation of patients with advanced
cancer does not necessarily mean the shortening of life. Several
authors have documented no difference in survival of both
sedated and non-sedated terminal patients.5,6,18,21 These are
important findings and they go a long way towards
establishing the legitimacy of the use of sedation in such
patients.
In the series of studies reviewed by Sales,1 delirium (39%)
and dyspnoea (38%) were the main refractory symptoms for
which sedation was used. Nausea and vomiting were
refractory in 6%. The reason for the high incidence of
intractable vomiting at Sungardens was that there were 5
patients (25%) with intestinal obstruction in a relatively small
total number (20) of patients.
Lack of uniform diagnostic criteria and the reporting of
more than 1 refractory symptom make comparison between the
results from Sungardens and other surveys difficult. The
median frequency of the use of sedation in the 13 studies
reviewed by Sales1 was 25%. The prevalence of sedation at
Sungardens (20%) is below this figure.
The studies reviewed by Sales showed survivals of between
1.5 and 3.9 days after beginning sedation. The short survival of
sedated patients has been shown to be a reflection of their
advanced stage of disease rather than the shortening of their
lives due to sedation.5,6,21
The absence of a resident doctor at Sungardens Hospice
contributed to a rather long delay in achieving complete relief
of the refractory symptoms, once sedation had begun. A second
factor was that the drugs used for sedation were administered
by continuous SC infusion using a syringe driver. Although
this means that the onset of sedation is slower, it does not
cause rapid over-sedation of patients and does not  require an
IV line. Continuous SC infusion by means of a syringe driver is
commonly used in palliative care internationally.22
Parenteral fluids are seldom used at Sungardens Hospice.
Most terminally ill patients stop eating and drinking during
the last few days of life without this causing them any
discomfort. The body’s metabolism undergoes a number of
significant changes as a result of diminished intake of food and
fluids. The metabolic rate slows down. Ketones and free fatty
acids, produced by the catabolism of the body’s own tissues,
become the main energy source. The process of catabolism also
produces water. Together with the reduction in the amount of
urine excreted, this means that the need for additional fluids is
greatly reduced.23,24 Although the actual needs of a sedated
dying person for food and fluids are not known, there is no
evidence that artificial feeding positively influences their
comfort or outcome.25 There is some evidence that artificial
feeding may do just the opposite.26-28 The main problem,
however, may be the symbolic nature of food and water.
Denying them to anyone, even someone who is dying, may be
perceived as cruel.29 Open communication with patients and
their families helps to ensure that joint decisions are made as
far as possible. At the same time it should be emphasised that
the main goal of care for the imminently dying person is
comfort. Any plan of action must be aimed primarily at
making the dying person comfortable. ‘A doctor has neither the
duty nor the right to prescribe a lingering death.’30
The dose of drugs for analgesia and sedation used at
Sungardens Hospice is similar to that used in other centres
around the world. Turner and colleagues31 from Sydney
reported a mean  daily dose of 66.2 mg of parenteral morphine
and a dose range of midazolam of 2.5 - 47 mg during the last 3
days of life. Thorns and Sykes32 from London report a mean
daily dose of 55.5 mg of parenteral morphine in a series of
terminal patients. Morita and colleagues33 in Japan reported
using a mean dose of 68 mg of morphine, 26 mg of midazolam
and 5 mg of haloperidol per day (Table II). These three studies
were reporting on the drug use of a sequence of consecutive
admissions and not specifically on those being sedated for
refractory symptoms. In a multicentre international study of
the use of sedation for refractory symptoms, Fainsinger
reported that the mean daily dose of midazolam was 33 mg
(range 5 - 180 mg).8
Although comparing results is difficult as the designs of the
studies are so different, the drug doses used at Sungardens
Hospice appear to be similar to those used in other centres in
England, Japan and Australia. They are also within the range




The small numbers in this study preclude generalisation. The
study highlights the need for clear definitions and guidelines
to ensure the best possible care for those patients nearing the
end of their lives who have intractable symptoms.
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Conclusion
This survey shows that the use of sedation in dying patients at
Sungardens Hospice is in line with several studies reported in
the international literature. An international consensus is
gradually emerging as common terminology and approaches
are being adopted. A new multicentre international study using
a standardised protocol is needed to confirm this consensus
especially with regards to the indications for sedation and the
drug dosages.
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